News | Contrast Media | September 12, 2017

Medical Imaging Drugs Advisory Committee (MIDAC) votes 13 to 1 to add warning of the possible risks of gadolinium retention

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

September 12, 2017 — The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly last week to recommend new labels on gadolinium-based contrast agents (GBCAs) warning of the possibility of gadolinium retention in the body following administration during magnetic resonance imaging (MRI) exams. The labels will further explain that linear GBCAs carry a greater risk than macrocyclic agents, and that there is a greater risk for certain patient populations, according to Medscape.

The meeting, held Sept. 8, brought FDA officials together with healthcare professionals, industry representatives, patients and patient advocacy groups to discuss the merit of changing the regulatory approach for GBCAs. Representatives from Guerbet, Bayer, Bracco and GE Healthcare were all present at the meeting.

Concerns have emerged about gadolinium-based contrast agents in recent years as research has suggested that gadolinium is retained in the body, particularly in the brain, after administration and could cause adverse health effects, particularly for patients with renal failure. The FDA issued a Drug Safety Communication in May 2017 titled “No Harmful Effects Identified With Brain Retention,” in which the agency said it had not identified any adverse health effects from gadolinium retained in the brain, but that it would continue its review. 

In a statement released before the Sept. 8 meeting, the FDA said, “FDA’s approach has been educational: alerting the public and clinicians to the retention phenomenon but not issuing any restrictions on use because toxic effects in humans have not been established.”

For more information: www.fda.gov

 

Related Content on MRI Gadolinium Retention in the Brain

FDA: No Harm in MRI Gadolinium Retention in the Brain

Recent Trends and Developments in Contrast Media

VIDEO: MRI Gadolinium Contrast Retention in the Brain

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Radiology Business

April 4, 2024 — FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging ...

Time April 04, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | FDA

March 27, 2024 — SyntheticMR announced that its next-generation imaging solution, SyMRI 3D, has received FDA 510(k) ...

Time March 27, 2024
arrow
News | Breast Imaging

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 08, 2024
arrow
News | Artificial Intelligence

March 1, 2024 — Royal Philips, a global leader in health technology, and magnetic resonance imaging (MRI) software ...

Time March 01, 2024
arrow
News | Cardiac Imaging

February 12, 2024 — According to the American Journal of Roentgenology (AJR), free-breathing cine-deep learning (DL) may ...

Time February 12, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | Radiology Business

January 25, 2024 — Esaote Group, a leading Italian innovator in medical imaging, today unveiled its new brand identity ...

Time January 25, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
Subscribe Now